The Manufacturers Life Insurance Company Raises Position in Humacyte, Inc. (NASDAQ:HUMA)

The Manufacturers Life Insurance Company grew its stake in shares of Humacyte, Inc. (NASDAQ:HUMA) by 30.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,575 shares of the company’s stock after buying an additional 10,656 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Humacyte were worth $248,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its stake in shares of Humacyte by 62.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock valued at $1,219,000 after acquiring an additional 97,931 shares during the last quarter. Principal Financial Group Inc. purchased a new position in shares of Humacyte in the second quarter worth approximately $83,000. nVerses Capital LLC bought a new position in shares of Humacyte in the second quarter worth approximately $28,000. Rhumbline Advisers grew its stake in Humacyte by 87.8% during the second quarter. Rhumbline Advisers now owns 110,919 shares of the company’s stock valued at $532,000 after acquiring an additional 51,858 shares in the last quarter. Finally, Endowment Wealth Management Inc. grew its holdings in Humacyte by 3.1% during the 2nd quarter. Endowment Wealth Management Inc. now owns 100,518 shares of the company’s stock valued at $482,000 after buying an additional 3,000 shares in the last quarter. 44.71% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on HUMA shares. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 price objective on shares of Humacyte in a research report on Friday, September 20th. TD Cowen restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of Humacyte in a research report on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research report on Monday, September 9th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Humacyte currently has an average rating of “Buy” and an average price target of $13.00.

Humacyte Trading Up 5.9 %

Humacyte stock opened at $4.34 on Tuesday. Humacyte, Inc. has a 12 month low of $2.48 and a 12 month high of $9.97. The company has a current ratio of 1.10, a quick ratio of 1.10 and a debt-to-equity ratio of 0.61. The firm has a market cap of $546.23 million, a PE ratio of -3.06 and a beta of 1.38. The stock’s 50 day simple moving average is $4.99 and its two-hundred day simple moving average is $5.96.

Insider Buying and Selling

In related news, Director Brady W. Dougan sold 427,459 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total transaction of $1,855,172.06. Following the completion of the sale, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. This trade represents a 17.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Laura E. Niklason sold 261,369 shares of the company’s stock in a transaction on Wednesday, November 20th. The shares were sold at an average price of $4.40, for a total value of $1,150,023.60. Following the completion of the transaction, the chief executive officer now directly owns 1,730,884 shares in the company, valued at approximately $7,615,889.60. This trade represents a 13.12 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,500,000 shares of company stock valued at $6,606,799. 11.20% of the stock is owned by company insiders.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.